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Vitamin D3 Transactivates The Zinc and Manganese 
Transporter SLC30A10 Via The Vitamin D Receptor 
Tatiana Claro da Silvaa, Christian Hillera, Zhibo Gaia, Gerd A. Kullak-Ublicka,* 
aDepartment of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, 
Switzerland 
Abstract 
Vitamin D3 regulates genes critical for human health and its deficiency is associated with an 
increased risk for osteoporosis, cancer, diabetes, multiple sclerosis, hypertension, 
inflammatory and immunological diseases.  To study the impact of vitamin D3 on genes 
relevant for the transport and metabolism of nutrients and drugs, we employed next-
generation sequencing (NGS) and analyzed global gene expression of the human-derived 
Caco-2 cell line treated with 500 nM vitamin D3. Genes involved in neuropeptide signaling, 
inflammation, cell adhesion and morphogenesis were differentially expressed. Notably, 
genes implicated in zinc, manganese and iron homeostasis were largely increased by 
vitamin D3 treatment. An ∼10-fold increase in ceruloplasmin and ∼4-fold increase in 
haptoglobin gene expression suggested a possible association between vitamin D and iron 
homeostasis. SLC30A10, the gene encoding the zinc and manganese transporter ZnT10, 
was the chiefly affected transporter, with ∼15-fold increase in expression. SLC30A10 is 
critical for zinc and manganese homeostasis and mutations in this gene, resulting in impaired 
ZnT10 function or expression, cause manganese intoxication, with Parkinson-like symptoms. 
Our NGS results were validated by real-time PCR in Caco-2 cells, as well as in duodenal 
biopsies taken from healthy human subjects treated with 0.5 μg vitamin D3 daily for 10 days. 
In addition to increasing gene expression of SLC30A10 and the positive control TRPV6, 
vitamin D3 also increased ZnT10 protein expression, as indicated by Western blot and 
cytofluorescence. In silico identification of potential vitamin D responsive elements (VDREs) 
in the 5’-flanking region of the SLC30A10 promoter and dual-luciferase reporter assay 
showed enhanced promoter activity in the presence of vitamin D receptor (VDR) and retinoid 
X receptor (RXR) constructs, as well as vitamin D3, but not when one of these factors was 
absent. Electrophoretic mobility shift assay (EMSA) and competition EMSA revealed binding 
of select sequences, namely, nt -1623/-1588 and nt -1758/-1723 relative to the transcription 
start site, to VDR-containing nuclear extracts. In conclusion, we have shown that vitamin D3 
transactivates the SLC30A10 gene in a VDR-dependent manner, resulting in increased 
ZnT10 protein expression. Because SLC30A10 is highly expressed in the small intestine, it is 
possible that the control of zinc and manganese systemic levels is regulated by vitamin D3 in 
the intestine. Zinc, manganese and vitamin D are important for bone metabolism and brain 
health. Future examination of a possible role for supplementation or chelation of zinc and 
manganese, alongside vitamin D3 administration, will further our understanding of its 
potential benefit in the treatment of specific illnesses, such as osteoporosis and Parkinson’s 
disease. 
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1. Introduction 
Vitamin D is involved in several physiological processes, ranging from inflammation to 
glucose homeostasis and blood pressure, to name a few [1].  Deficiency in vitamin D is 
pandemic [2] and is correlated with asthma, diabetes, cancer and neuropsychiatric disorders 
[3]. While vitamin D can be obtained from fatty fish and fortified foods, its main natural source 
is the provitamin D, 7-dehydrocholesterol, found in the skin. Photochemical conversion of 7-
dehydrocholesterol, initiated by skin exposure to UV light, is the first step in the production of 
the biologically active vitamin D hormone. The product of this conversion is carried to the 
liver, where it is transformed into 25-hydroxyvitamin D (25OHD), which is then oxidized, 
predominantly in the kidney, to form the active hormone 1,25-dihydroxyvitamin D (1,25D), or 
vitamin D3. To exert its gene regulatory effect, vitamin D3 binds to the vitamin D receptor 
(VDR), which in turn dimerizes with the retinoid-X receptor (RXR) and binds vitamin D 
response elements (VDREs) in the promoter region of target genes, culminating in 
transcriptional activation or repression. Genes thus regulated include the calcium channel 
transient receptor potential vanilloid 6 (TRPV6) [4], the vitamin D3 24-hydroxylase CYP24A1 
[5] and the organic anion transporting polypeptide 1A2 (SLCO1A2; OATP1A2) [6]. Our 
present data shows that treatment of human derived Caco-2 cells with vitamin D3 altered 
gene expression of these and other genes relevant for a variety of physiological processes, 
including drug metabolism and transport. Iron homeostasis was among the most affected 
processes and may suggest that a correlation between vitamin D3 levels and iron regulation 
exists at the molecular level. Our results also indicate that expression of the SLC30A10 
gene, as well as its encoded protein, the zinc (Zn) and manganese (Mn) transporter ZnT10, 
are augmented by vitamin D3 treatment in Caco-2 cells. SLC30A10 mRNA is predominantly 
expressed in human liver, brain, testis and small intestine [7, 8]. Missense and nonsense 
mutations in this gene, impairing ZnT10 expression or cell surface trafficking, cause 
manganism – a Parkinson-like autosomal recessive disease characterized by dystonia, 
hypermanganesemia, steatosis, cirrhosis and polycythemia [9]. By means of its Mn efflux 
action, ZnT10 protects the CNS from manganese toxicity and ZnT10 dysfunction leads to 
accumulation of Mn in the liver and nervous system [10], even in patients without prior history 
of environmental exposure to high Mn levels [8]. Zn and Mn are classified as trace elements 
or micronutrients because they are essential for human health albeit needed in small 
quantities, whereas at high concentrations, they exhibit toxic effects [11]. It is interesting to 
note that, in addition to the renowned vitamin D and calcium contributions, Zn and Mn are 
crucial for bone metabolism [12].  They are absorbed from the intestine [10], where the gene 
encoding ZnT10, SLC30A10, is highly expressed at the mRNA level [7] and where the VDR 
is also abundant [13]. Because our results indicate that vitamin D3 induces SLC30A10 gene 
and protein expression, it is likely that the control of Zn and Mn systemic levels begins in the 
intestine and is dependent on the vitamin D nutritional status.  
 
2. Material and Methods 
2.1. Cell Culture 
The human-derived Caco-2 cell line (LGC Promochem, Molsheim, Switzerland) was cultured 
in Dulbecco’s modified Eagle’s medium (ThermoFisher) containing 10% fetal bovine serum 
(Chemie Brunschwig) and 1000 U/mL and 1000 g/mL penicillin and streptomycin, 
respectively (Invitrogen, Carlsbad, CA). Cells were maintained at 37°C, in a humidified 
atmosphere containing 5% CO2. 
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2.2. Next Generation Sequencing (NGS) 
Caco-2 cells were treated with 500 nM 1,25 Dihydroxyvitamin D3 (vitamin D3) or vehicle 
(ethanol; EtOH) for 8h, 24h, 48h and 72h. Cells were harvested in TRIzol® and total RNA 
was isolated using the guanidinium thiocyanate-phenol-chloroform extraction method. At the 
Functional Genomics Center Zurich, the isolated RNA was reverse-transcribed and amplified 
by PCR, then next-generation sequencing on the Illumina HiSeq 2000 (TruSeq SBS Kit v3-
HS (Illumina)) was performed. Changes were considered significant when p value ≤ 0.05 and 
the increase or decrease in expression was at least 40% (log2 ratio ≥ 0.5 or ≤ -0.75) 
compared to the vehicle control (EtOH). MetaCore online service (Thomson Reuters) was 
employed for gene ontology and network analysis. Select genes altered by vitamin D3 in the 
NGS data were chosen for further investigation. 
2.3. Vitamin D3 administration in healthy human volunteers 
In a prospective single-center study performed at the University of Zurich, six female and four 
male healthy volunteers (aged 24-29 years, mean 26 years, median 26 years) self-
administered 1,25 dihydroxyvitamin D3 (Rocaltrol®) 0.5 μg per day for 10 days. Duodenal 
biopsies were collected by gastroscopy before (“FIRST” gastroscopy) and after (“SECOND” 
gastroscopy) the onset of Rocaltrol® administration and were immediately frozen in liquid 
nitrogen. Subsequently, biopsies were analyzed by real-time PCR (RT-PCR) as described in 
the next section (2.4.), to confirm gene changes observed in the NGS data. This study was 
performed in conformity with the Good Clinical Practice guideline ICH E6 after having been 
approved by the ethical committee of the Canton of Zurich (license number 2012-0051) and 
registered at clinicaltrials.gov (NCT01856348). All volunteers signed the informed consent. 
2.4. Analysis of duodenal biopsies and Caco-2 cells by real-time PCR  
Extraction of RNA from duodenal biopsies and Caco-2 cells was performed using the 
Nucleospin miRNA kit (Macherey-Nagel, Inc.). Prior to processing, duodenal biopsies were 
homogenized with a 1.5 mL pestle (VWR cat. # 47747-358, European Article # 431-0094) 
following recommendations from the Nucleospin miRNA kit’s manufacturer. After tissue 
homogenization, biopsies and Caco-2 cells were processed similarly. Extracted RNA was 
subsequently evaluated by RT-PCR for selected drug and nutrient transporters, using 
TaqMan probes (ThermoFisher). Data obtained was normalized to the housekeeping genes 
villin (biopsies) or beta-actin (Caco-2 cells). 
2.5. Isolation of a total membrane fraction from cultured Caco-2 cells.  
Caco-2 cells grown in 10 mm petri dishes were treated with 500 nM 1,25 dihydroxyvitamin D3 
(vitamin D3) or vehicle (ethanol; EtOH) for 72h with refreshment of vitamin D3 or EtOH every 
24h. The following procedure was performed on ice. Briefly, cells were washed 3x in 10 mL 
of 0.9 % (w/v) NaCl solution, followed by 1x addition of 10 mL 250 mM sucrose solution. 
Subsequently, 3 mL ice-cold 5 mM sucrose solution, containing 5 mM 
phenylmethanesulfonyl fluoride (PMSF; freshly added from a 200 mM stock in EtOH) and 1 
mg/ml antipain/leupeptin (freshly added from 1 mg/ml stock each) was added and cells were 
scraped with a rubber policeman, then transferred to a tight fitting glass-teflon potter on ice 
and homogenized with 20 strokes at full speed. Homogenate was then centrifuged at 4 °C for 
10 min at 2950 rpm (900 gav) in a Sorvall SS34 rotor and the supernatant was carefully 
removed and centrifuged at 4 °C for 20 min at 9600 rpm (8500 gav) in a Sorvall SS34 rotor. 
Next, the resulting supernatant was carefully removed and centrifuged at 4 °C for 1h, at 
38’200 rpm (100’000 gav) in a TFT 65.13 rotor or at 36’400 rpm (100’000 gav) in a TFT 70.38 
rotor. After complete removal of the supernatant, ~500 µL of a 250 mM sucrose solution 
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containing protease inhibitors was added to the precipitate and this suspension was 
homogenized with a 1 ml syringe and a thin needle. Approximately 10-20 microlitter of the 
resulting solution was separated for protein determination and the remaining membrane 
fraction was stored in liquid nitrogen until use. 
2.6. Western blotting 
Lysates containing 20 μg of protein from the isolated Caco-2 membrane fraction described 
above were separated by SDS-PAGE and blotted on polyvinylidene difluoride membranes 
(Millipore). Membranes were blocked with TBS containing 0.1% Tween 20 (TBST) and 3% 
BSA, for 1 hour, at room temperature. The primary antibodies rabbit anti-SLC30A10 (Sigma-
Aldrich, HPA017989) and the plasma membrane control goat anti-Na+K+ATPase (Santa 
Cruz, sc-16041) were then incubated overnight at 4°C. After washing the membranes with 
TBST, blots were treated with horseradish peroxidase conjugated secondary antibodies at 
room temperature for 1 hour, washed again with TBST and developed using the ECL Plus 
detection system (Amersham Biosciences, Little Chalfont, UK).  
2.7. Cytofluorescence 
Caco-2 cells grown on3 mm slides were treated with 500 nM 1,25 Dihydroxyvitamin D3 
(vitamin D3) or vehicle (ethanol; EtOH) for 72h with refreshment of vitamin D3 or EtOH every 
24h. After treatment, cells were washed with cold PBS, fixed in 4% paraformaldehyde, and 
treated with 0.1% Triton X in PBS for 15 minutes and with 0.1% Tween-20 in 1% BSA/PBS 
for 30 minutes. Then, cells were incubated with rabbit anti-SLC30A10 (Sigma-Aldrich, 
HPA017989) antibody at 4°C overnight. Cells were then washed and incubated with 
secondary antibody for 1 hour at room temperature, in the dark. After being washed, cells 
were counterstained with 4’-6-diamidino-2-phenylindole (DAPI; Vector Laboratories) and 
slides were mounted and visualized under a fluorescent microscope (Leica DMI6000B). 
2.8. Identification of VDREs in silico and DNA constructs 
In silico analysis of the 5’-flanking region enclosing ∼3.6 kb upstream the transcription start 
site (TSS) and ∼211 bp downstream the ATG start codon, i.e., -3622/+211, of the SLC30A10 
promoter, revealed several conjectural vitamin D response elements (VDREs). This analysis 
was performed with the online transcription factor binding site prediction tools PROMO [14, 
15] and MatInspector [16, 17], as well as by visual inspection of canonical sites, based on 
sequences described in Toell et al [18]. This ∼3.8 kb region was then synthesized, cloned 
and subcloned into the pGL3 basic luciferase reporter vector (Promega) using GeneArt 
services, for subsequent dual-luciferase reporter assay. Briefly, the synthesized fragment 
was cloned into the pMK vector, carrying a kanamycin resistance gene, and was then 
subcloned into the Nhe/XhoI-digested pGL3 basic vector. Dual-luciferase reporter assay was 
carried out as described below (section 2.6.). In silico predicted VDREs were also 
incorporated in the design of oligonucleotides used in electrophoretic mobility shift assay 
(EMSA), as described in section 2.7. 
2.9. Dual-Luciferase Reporter Assay 
Caco-2 cells were seeded in 48-well plates and transiently transfected at a confluence of 
approximately 80%, on the next day. The transfection agent Fugene HD (Promega) was 
used to deliver DNA to the cells, in a transfection mixture containing 400 ng of the pGL3 
basic constructs (section 2.5.) and 200 ng of VDR and/or RXR expression plasmid in pCMX. 
The pCMX-VDR and pCMX-RXR plasmids were kindly donated by Dr. David Mangelsdorf 
(University of Texas Southwestern Medical Center, Dallas, TX). In each well, 100 ng of 
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phRG-TK Renilla reniformis luciferase reporter plasmid (Promega) was co-transfected to 
account for variations in transfection efficiency. An appropriate volume of 1α,25-
dihydroxyvitamin D3 (Sigma-Aldrich) or its vehicle EtOH, was added to each well 2h after 
transfection, to obtain a final vitamin D3 concentration of 500 nM. Twenty four hours post-
treatment, cells were lysed with 50 µL of the passive lysis buffer provided in the Dual-
Luciferase® Reporter (DLR™) Assay System kit (Promega) and 10 µL of lysate were 
transferred to a 96-well plate. Luciferase activity was measured with the substrates LAR II 
and Stop & Glo®, also included in the kit, using a GloMax-Multi detection system (Promega). 
Values obtained for firefly luciferase activity were normalized to renilla’s activity, as well as 
empty vectors such as pGL3-basic or pcDNA3.1. In each experiment, tested conditions were 
performed in triplicate. 
2.10. Electrophoretic Mobility Shift Assay 
Electrophoretic Mobility Shift Assay (EMSA) oligos were designed based on in silico 
predicted VDREs, with added 5’-AGCT (fwd) or 5’-GATC (rev) overhangs to allow for their 
radioactive filling-in reactions, as described previously [19] and indicated in table 2. They 
were annealed and subsequently labeled with [32P]-dATP, using Multiscribe reverse 
transcriptase (Life Technologies). Nuclear extracts from Caco-2 cells at 70-80% confluence 
were quantified with the Pierce™ BCA Protein Assay Kit (Thermo Scientific). Appropriate 
binding reactions were performed using NE-PER kit (ThermoScientific) and carried out as 
described [19]. The oligonucleotide named VDREcon, carrying the VDRE consensus 
sequence AGGTCA in a DR3 repeat, was used as positive control in EMSA. In competition 
EMSA, unlabeled VDREcon was employed at 100 ng (Cold VDREcon_1) and 200 ng (Cold 
VDREcon_2), to compete with 150 ng of the labeled oligos for the VDR.  
2.11. Statistical Analysis 
Gene ontology (GO) and Network analysis of the next-generation sequencing data were 
performed with the MetaCore online software (Thomson Reuters). Dual-luciferase assay data 
were analyzed with One-way analysis of variance followed by Dunnett’s post-hoc test, using 
GraphPad 5.0. Error bars represent the standard error of the mean values from at least 3 
experiments. Differences between treatment and controls (*) were considered significant 
when p≤0.05.  
 
3. Results 
3.1. Global effects of Vitamin D3 in Caco-2 cells: Next Generation Sequencing (NGS) 
Vitamin D3 plays an important role in the regulation of several SLC transporters and 
metabolizing enzymes. Caco-2 cells were treated with vitamin D3 for 24h and total RNA was 
extracted and analyzed by NGS. Changes in gene expression were considered significant 
when p value ≤ 0.05 and expression was at least 41% increased (log2 ratio ≥ 0.5) or 
decreased (log2 ratio ≤ -0.75), compared to the vehicle control (EtOH). Consistent with 
previous reports, vitamin D3 increased expression of genes implicated in its own catabolism, 
namely, CYP24A1 and CYP3A4, as well as genes involved in calcium homeostasis, such as 
the calcium channel TRPV6, implicated in intestinal calcium absorption. The acknowledged 
mechanism by which these inductions occur is by VDR binding to VDREs in the promoter 
regions of these genes [4, 20-22]. Of all 208 upregulated and 352 downregulated genes 
significantly affected (Figure 1), vitamin D3 24-hydroxylase CYP24A1 showed the strongest 
change in expression, with an increase of above 1000-fold and was followed by the calcium 
channel TRPV6, with over 100-fold increase (log2 ratio(24h) = 6.989; p-value = 5.37e-56). Also 
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consistent with previous reports [23], vitamin D3 increased expression of the cytosolic 
sulfotransferase SULT1C2. The UDP glycosyltransferase UGT1A1 and the retinoic acid 
hydroxylase and CYP26A1 were among the relevant metabolizing enzymes whose 
expression was augmented by vitamin D3 (Table 1). 
Table 1: Gene expression of metabolizing enzymes significantly affected by Vit. D treatment in Caco-2 
cells for 24h. Gene expression levels are quantified as log2 ratio of treatment (vitamin D3) vs. control 
(EtOH) and converted with 2^(log2 ratio) to denote fold change: 0.5 corresponds to 1.41 fold change, i.e., 
41% increase in gene expression.  
                                       
 
NGS data endorsed our previous observations that vitamin D3 transactivates the organic 
anion transporting polypeptide 1A2 (OATP1A2; SLCO1A2 gene) and the proton-coupled 
folate transporter (PCFT; SLC46A1 gene) [6, 24]. Here, their expression levels increased by 
approximately 2-fold each (Table 2). Vitamin D3 also enhanced expression of nutrient 
transporters such as the fatty acid transport protein (FATP2; SLC27A2) and the 
carnitine/acylcarnitine carrier (CAC; SLC25A20). In contrast, expression of genes encoding 
the organic anion transporter 4 (OAT4; SLC22A11) and the glucose transporter 2 (GLUT2; 
SLC2A2) was considerably reduced. In addition to the OATP1A2, PCFT and OAT4, which 
transport endogenous as well as drug molecules into the cell, e.g., fexofenadine (OATP1A2), 
methotrexate (PCFT) and torasemide (OAT4), the efflux transporters multidrug resistance-
associated protein 2 (MRP2) and the P-glycoprotein-1 (P-gp) also responded to vitamin D3 
treatment in Caco-2 cells (Table 2).  
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Table 2: Gene expression of nutrient and drug transporters significantly affected by Vit. D treatment in 
Caco-2 cells for 24h. Gene expression levels are quantified as log2 ratio of treatment (vitamin D3) vs. 
control (EtOH) and converted with 2^(log2 ratio) to denote fold change: 0.5 corresponds to 1.41 fold 
change, i.e., 41% increase in gene expression.  
                     
 
Network analysis shows iron homeostasis among the top differentially expressed pathways 
due to vitamin D3 treatment, alongside with neuropeptide signalling, inflammation, cell 
adhesion and morphogenesis (Figure 1D). These results agree with several reports on the 
putative or confirmed modulatory effects of vitamin D in innate and adaptive immunity, cell 
growth and differentiation [10, 25-27]. Among the genes involved in iron homeostasis, the 
iron oxidase ceruloplasmin (∼10-fold increase), the hemoglobin binding protein haptoglobin 
(∼4-fold increase), and SLC46A1, also known as the heme-iron carrier 1 (HCP1) [28], had 
the most remarkable increase in gene expression. In contrast, expression of SLC39A2 and 
the tweety family member 1 (TTYH1) were significantly reduced (Table 3). While TTYH1 is 
possibly an iron transporter [29], SLC39A2 was shown to play an important role in iron 
homeostasis in zinc deficient mice [30]. SLC39A2 is part of the ZIP (SLC39) family, 
implicated in zinc, iron and/or manganese transport [31].  
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Table 3: Degree of change in gene expression for selected pathways affected by Vit. D treatment of 
Caco-2 cells for 24 hours 
 
CP = ceruloplasmin, HP = haptoglobin, SLC46A1 = PCFT/HCP1, FTH1 = ferritin, HFE = 
hemochromatosis, SLC40A1 = ferroportin, EPOR = erythropoietin, TTYH1 = tweety family member 1. 
Numbers in parentheses indicate gene expression levels quantified as Log2 ratios. When converted 
with 2^(log2 ratio), they indicate fold changes: (0.5) corresponds to a 1.41 fold, or 41%, change in gene 
expression. 
 
Vitamin D has been shown to have beneficial effects in neurological diseases where 
neuropeptide, especially glutamate, signaling is dysregulated, such as schizophrenia [32] 
and Parkinson’s disease [33-35]. Our NGS data shows an ∼50% increase in the glutamate 
transporter gene SLC1A3 (Table 2). While genes involved in peptide, amide and sulfur 
compound binding, glutathione transferase and the major histocompatibility complex (MHC) 
class II are downregulated by vitamin D3 in Caco-2 cells (Figure 1C), genes involved in 
enzymatic catalysis, heme and oxygen binding and serine-type endopeptidase activity are 
upregulated, as revealed by GO analysis (Figure 1B).  
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Figure 1. Effect of vitamin D treatment on gene expression patterns in Caco-2 cells. (A) 
Summary of differentially expressed genes between Vit D treatment for 24 hours and vehicle control 
(EtOH).  Genes that are differentially increased or decreased after Vit D treatment are indicated by 
orange and green bars, respectively. Cut off 1.4-fold, p < 0.05. Of all 560 genes with significantly 
changed expression after Vit D treatment for 24 hours, 208 genes are increased and 352 genes are 
reduced.  (B) Gene ontology (GO) analysis of genes with a ≥ 1.4 fold increased expression (orange 
bars). (C) GO analysis of genes with a ≥ 1.4 fold decreased expression (green bars).  (D) Network 
analysis of genes with a change of expression of ≥ 1.4 fold across treatment groups. The top 5 results 
are listed. All analyses were performed with the MetaCore online software (Thomson Reuters). 
 
Of all genes that showed increased expression with vitamin D3 treatment, SLC30A10 was the 
fourth most strongly affected. It was also the chief affected transporter gene, with ∼15-fold 
increase in expression (Table 2). A concomitant ∼45% decrease in expression of the other 
zinc transporter, SLC39A2, is noteworthy. These zinc transporters work in opposite 
directions to maintain zinc homeostasis. While members of the ZnT (SLC30) family reduce 
Zn2+ cytoplasmic concentrations via efflux through the plasma membrane or uptake into 
cytoplasmic organelles, ZIP (SLC39) transporters increase cytoplasmic zinc concentrations 
by zinc uptake from the extracellular space or efflux from intracellular storage organelles [36]. 
SLC30A10 is mostly located in the brain, retina, liver and small intestine [7, 37], while 
SLC39A2 has a widespread tissue distribution [38].  
3.2. Vitamin D3 increases SLC30A10 expression in duodenal biopsies and Caco-2 cells: 
Real-time PCR 
Real-time PCR validated the NGS observations of strong induction of SLC30A10 by vitamin 
D3. Caco-2 cells were treated with 500 nM 1,25 dihydroxyvitamin D3 (vitamin D3) or vehicle 
(EtOH) for 8h, 24h, 48h and 72h and the effect of vitamin D3 on SLC30A10 was already 
observed after 8h of treatment, while it peaked at 48h (Figure 2). This rapid onset, but slow 
reaching of steady-state may suggest a complex mechanism for SLC30A10 induction by 
vitamin D3, possibly with genomic (VDR-mediated regulation of transcription) and non-
genomic (activation of signal transduction pathways upon binding to a cell surface receptor) 
vitamin D3 modes of action [1]. A strong vitamin D3 effect was also observed for TRPV6 at all 
time points. Because TRPV6 is known to have a functional VDRE [4, 22] and is highly 
expressed in the duodenum [39], it was considered a suitable positive control in the RT-PCR 
measurements in Caco-2 cells, as well as in human duodenal biopsies. Biopsies were 
collected from healthy human volunteers, before and after oral administration of 0.5μg 1,25-
dihydroxyvitamin D3 for 10 days. All biopsy-derived mRNA measurements were normalized 
to villin. TRPV6 induction was noticeable in 70% of the duodenal biopsies, while SLC30A10 
expression was augmented in 60% of the biopsies (Figure 3B).   
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Figure 2: Vitamin D3 increases SLC30A10 gene expression time-dependently. Gene expression 
measured with RT-PCR for SLC30A10 (A) and TRPV6 (B) and normalized to beta actin, from Caco-2 
cells treated with 500 nM vitamin D3 or EtOH, at different time-points.  
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Figure 3: Vitamin D3 oral administration increases SLC30A10 and TRPV6 gene expression in 
duodenal biopsies. RT-PCR of duodenal biopsies collected before (FIRST) and after (SECOND) 
Rocaltrol® 10 days-treatment, in human healthy volunteers. Biopsies were processed as described in 
methods, sections 2.3 and 2.4. 
3.3. Vitamin D3 increases ZnT10 protein expression in Caco-2 cells: Western blotting and 
cytofluorescence 
Protein expression at the cell surface is critical for the ZnT10 efflux activity and its protective 
role against Mn toxic accumulation. Mutations in SLC30A10 that result in ZnT10 retention in 
the endoplasmic reticulum are linked to cases of familial parkinsonism, presenting with Mn 
accumulation in the liver and the CNS [8, 40]. To determine if the vitamin D3-induced 
augmentation of SLC30A10 gene expression leads to an increase in ZnT10 protein at the 
cell surface, we first seeded Caco-2 cells on microscope slides or 10 mm petri dishes and 
then treated the cells with vitamin D3 or control (EtOH). We subsequently prepared slides for 
immunofluorescence detection (section 2.7) and isolated the membrane fraction of cells 
grown in the petri dishes (section 2.5) for Western blotting (section 2.6), using an anti-
SLC30A10 antibody. Vitamin D3 treatment clearly increased ZnT10 protein levels at the cell 
surface, as shown by enhanced immunofluorescence along the cell borders in treated cells, 
compared to control (Figure 4B). A notable increase in immunoblotting signal for ZnT10, but 
not the negative control Na+/K+-ATPase, is also observed in vitamin D3-treated, but not 
untreated cells (Figure 4A). These observations support the hypothesis that vitamin D3 is 
important for SLC30A10-mediated Zn and Mn homeostasis.  
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Figure 4: ZnT10 expression is induced by Vitamin D3 treatment. A, representative western blot of 
ZnT10 and the cell surface control Na+-K+ ATPase, from isolated membrane fractions of Caco-2 cells 
treated with vehicle (Cont) or Vitamin D3 (VitD). B, representative staining of Caco-2 cells from vehicle 
(Cont) or vitamin D3 (VitD) treatment groups for ZnT10 protein (red). Cells were counterstained with 
DAPI (blue). 
3.4. Vitamin D3 activates the SLC30A10 promoter: reporter gene assay 
VDR-responsive elements (VDREs) have been found in numerous genes important for 
calcium homeostasis and vitamin D metabolism, such as TRPV6 and CYP24A1, as well as 
genes that do not appear to have direct implications in calcium homeostasis, such as 
SLCO1A2 and SLC46A1 [6, 24]. These genes respond to vitamin D3 with an increase in 
gene expression. Our results show that vitamin D3 increases SLC30A10 expression at the 
mRNA and protein levels, prompting us to study whether this is a VDR-mediated effect. We 
employed the in silico prediction tools PROMO [14, 15] and MatInspector [16, 17], as well as 
visual inspection [18] and examined the region in the SLC30A10 promoter encompassing -
3622 nucleotides in the 5’-flanking region of the gene, relative to the TSS (position +1), and 
211 nucleotides upstream the ATG start codon, i.e., -3622/+211 or ∼3.8 kb, using RefSeq 
NG_032153.1 from the National Center for Biotechnology Information database (Figure 4A). 
Because 13 conjectural VDREs were predicted, the DNA sequence corresponding to ∼3.8 kb 
upstream the ATG was used to construct a reporter plasmid in pGL3 basic, as described in 
section 2.5 and indicated in the cartoon in Figure 4B. The resulting construct was tested for 
promoter activity in a dual-luciferase assay. Classically, heterodimerization of the nuclear 
VDR with RXR is necessary for VDR-dependent induction to occur. After cotransfecting 
Caco-2 cells with VDR-pCMX and RXR-pCMX, or with the negative control vector pcDNA3.1, 
the SLC30A10 promoter construct was incubated with vitamin D3 or vehicle (EtOH). As 
shown in figure 4B, luciferase activity increased significantly in the presence of VDR, RXR 
and vitamin D3, but not with either transcription factor alone or when vitamin D3 was replaced 
with EtOH. This observation indicates that the SLC30A10 promoter is transcriptionally 
activated by vitamin D3 and that VDR and RXR are required to confer this induction.   
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Figure 5: SLC30A10 promoter sequence and reporter gene activity. A) 5’-flanking region ∼3.8 Kb 
upstream the SLC30A10 gene start codon (ATG). Putative VDREs and the ATG start codon are 
highlighted in blue and red, respectively, and EMSA oligos are enclosed in boxes. NCBI RefSeq 
NG_032153.1. B) SLC30A10 promoter activity measured by dual-luciferase reporter assay. Caco-2 
cells were transiently transfected with the SLC30A10 promoter region -3622/+211 (relative to the TSS) 
in the luciferase reporter vector pGL3 basic. Expression plasmids of the human VDR (pCMX) and/or 
RXR (pCMX) or empty vector (pCDNA3.1), as well as the transfection efficiency control phRG-TK 
Renilla reniformis luciferase reporter plasmid, were co-transfected. Vitamin D3 or EtOH was added 2h 
post-transfection, in a final concentration of 500 nM and incubated for 24h, after which cells were 
harvested and luciferase and renilla activities measured. Firefly luciferase values were normalized to 
renilla’s values in each well, and data was normalized to the appropriate empty vectors. Bars 
represent the standard error of the mean for three independent experiments, each performed in 
triplicate. Results were analyzed with One-way analysis with Dunnett’s post-hoc test in GraphPad 
5.0b, with differences being considered significant (*) when p≤0.05. 
3.5. VDR binds to the SLC30A10 promoter region: electrophoretic mobility shift assay 
After showing that the 5’-flanking region of the SLC30A10 gene is activated by vitamin D3 in 
reporter gene assays and may contain a functional VDRE, we aimed to identify the VDRE or 
VDREs responsible for this effect. Based on the in silico predicted VDRE sequences, we 
designed oligos with 5’-AGCT (fwd) (Table 4) or 5’-GATC (rev) overhangs, to allow for their 
radioactive filling-in reactions, and tested them in EMSA (Table 2). As evidenced from the 
resulting DNA-protein shift (Figure 5A), nuclear extracts from human-derived Caco-2 cells 
showed protein binding activity to DNA sequences located at -1623/-1588 (oligo #1), and -
1758/-1723 (oligo#2), but not -3367/-3332 (oligo#3), from the transcription start site. As a 
positive control we used the EMSA probe that we showed previously to correspond to the 
SLCO1A2 VDRE at +202/+216 [6]. We then used a molar excess of cold probe containing a 
canonical VDRE sequence, namely VDREcon, to compete with radioactively labeled (hot) 
oligo#1 and oligo#2 for VDR binding (Figure 5B). Disappearance of the DNA-protein shift 
band in the presence of competitor confirms that the VDR binds to the SLC30A10 promoter 
region, at nt -1623/-1588 (oligo #1), and nt -1758/-1723 (oligo#2) relative to the TSS. 
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Table 4: Top strands of oligonucleotides used as EMSA probes, numbered relative to the 
transcriptional start site of the human SLC30A10 gene (NCBI RefSeq NG_032153.1). 
 
 
 
Figure 6: EMSA showing the VDRE motifs in the SLC30A10 promoter. Double-stranded, radiolabeled 
oligos at -3367/-3332 (oligo#3), -1623/-1588 (oligo#1) and -1758/-1723 (oligo#2) were co-incubated 
with binding reaction containing Caco-2 nuclear extract. A) Only oligos #1 and #2 showed DNA-protein 
shift bands similar to the positive control OATP1A2 DR3 motif +202/+216. B) Competition EMSA 
whereby 200 ng of either radiolabeled oligo#1 or oligo#2 were competed off with cold VDRE 
consensus probe (VDREcon) using 100 ng (Cold VDREcon_1) or 200 ng (Cold VDREcon_2). 
 
4. Discussion 
Vitamin D is essential for human health. Its active form, the hormone 1,25-dihydroxyvitamin 
D (1,25D), or vitamin D3, has pleiotropic effects beyond calcium homeostasis and bone 
metabolism. Vitamin D deficiency is associated with increased risk for osteoporosis, cancer, 
diabetes, multiple sclerosis, hypertension, inflammatory and immunological diseases, among 
other illnesses [41]. Classically, the vitamin D3 effects are mediated by the VDR, which in 
turn is estimated to regulate the expression of about 500 human genes [1]. Our current NGS 
results from vitamin D3-treated Caco-2 cells corroborated previous observations that vitamin 
D3 increases expression of the vitamin D hydroxylase CYP24A1 (Figure 1B), SULT1C2 and 
SLCO1A2 [4, 6, 20-24] (Table 2), as well as of genes involved in neuropeptide signalling, 
inflammation, cell adhesion and morphogenesis [10, 25-27] (Figure 1D). In line with the 
pleiotropic nature of vitamin D3 effects, we observed alterations in genes with distinct 
functions, many of which are important for nutrient and drug transport, as well as phase I and 
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phase II metabolism (Tables 1 and 2). Iron and heme metabolism were revealed by network 
analysis as greatly affected by vitamin D3 treatment in Caco-2 cells. These observations 
were further corroborated by GO analysis, where genes involved in oxygen and heme 
binding were among those affected most by vitamin D3 treatment (Figure 1B). While 
additional experiments would be useful to verify these outcomes in vivo, for example, the 
effect of VDR knockout on iron homeostasis, our current results may provide a preliminary 
molecular basis for a conceivable link between vitamin D status and iron homeostasis. This 
link can be inferred from in vivo animal studies and clinical human data. For instance, four 
weeks’ administration of high doses of dietary vitamin D3 to Wistar rats enhanced iron 
intestinal absorption and hepatic iron stores [42], while, conversely, rats fed an iron deficient 
diet exhibited decreased serum vitamin D and bone mineral density (BMD) [43]. In a 
randomized controlled double-blind trial with iron-deficient menstruating women, 
enhancement of erythropoiesis and iron status was only achieved when skimmed milk was 
fortified with vitamin D and iron, but not iron alone [44]. Although a direct vitamin D 
involvement pends confirmation, vitamin D deficiency appears to increase the risk of anemia 
in healthy female children and adolescents [45]. Iron deficiency has been hypothesized as a 
risk factor for osteoporosis [46]. Overall, our data support an association between the effects 
of vitamin D and iron at the molecular level that would warrant further investigation.  
Expression of various transporter genes was significantly altered by vitamin D3 in Caco-2 
cells. SLC30A10, encoding the zinc and manganese transporter ZnT10, was the transporter 
with the highest increase in gene expression, with remarkable increase in protein expression 
as well, and we hereby show that transactivation by the VDR is responsible, at least partly, 
for this response. Zinc and manganese are trace elements whose concentrations need to be 
tightly regulated to prevent the toxic effects of their accumulation in the body. Zinc is required 
for the activity of several enzymes, including DNA and RNA polymerases, for the immune 
system and as a structural component of transcription proteins. Among the many 
pathological consequences of Zn deficiency are growth impairment, dermatitis, diarrhea and 
neuropsychological diseases [47], whereas surges in its systemic levels correlate with 
anemia, leukopenia, neutropenia, copper and iron deficiency [48]. Manganese is important 
for bone development, lipid, carbohydrate and amino acid metabolism [11], but in high 
concentrations, causes parkinsonism, dystonia, hypermanganesemia, steatosis, cirrhosis 
and polycythemia [9]. The need to keep these micronutrients at a narrow concentration range 
is partly accomplished by the strict control of their transport in and out of the cell or 
intracellular compartments. The metal ion transporter families SLC39 (ZIP) and SLC30 
(ZnT), work in opposite directions to ensure zinc and manganese homeostasis. ZIP 
transporters increase cytoplasmic zinc concentrations via zinc uptake from the extracellular 
environment or efflux from intracellular storage compartments, while ZnT transporters move 
these ions out of the cell or into intracellular storage organelles, thereby decreasing their 
cytoplasmic levels [31, 36]. There are 10 identified members of the ZnT family: ZnT1-10. 
The gene encoding ZnT10, SLC30A10, is chiefly expressed in the liver, brain, testis and 
small intestine [7, 8] and is regulated by zinc via a zinc transcriptional regulatory element 
(ZTRE) [49]. Our results indicate that SLC30A10 expression is modulated by vitamin D3, via 
the VDR. Upon treatment with vitamin D3, we observed an increase in SLC30A10 mRNA and 
protein in Caco-2 cells and in human biopsies, prompting us to investigate a possible 
involvement of the VDR. The augmentation in SLC30A10 promoter activity strictly in the 
presence of the VDR, RXR and vitamin D3, as well as EMSA identification of VDREs located 
in the 5’-flanking region of the SLC30A10 gene, supported a VDR-mediated transactivation. 
In view of the pandemic vitamin D deficiency and widespread supplementation, it would be 
interesting to understand the physiological and pharmacological implications, if any, of this 
SLC30A10/ZnT10 induction by vitamin D3. Theoretically, the ultimate consequence would be 
a reduction in cytoplasmic levels of Zn and Mn concomitant with a rise in their levels in 
storage organelles and in the extracellular fluid. It would be tempting to speculate that 
vitamin D3 stimulates release of these metal ions into the circulation, to reach organs in need, 
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while aiding vitamin D in some of its physiological actions. For instance, vitamin D3, Zn and 
Mn have osteoprotective properties and stimulate bone formation [12]. Zinc has been 
suggested as an additional supplement in treatment and prevention of osteoporosis [50] and 
a possible participation of Mn in the mechanism of osteoporosis has been proposed [51]. It is 
still unclear whether there is a synergism between vitamin D3, Zn and Mn, but symptoms of 
some pathologies may suggest an important link between these nutrients. In inflammatory 
bowel disease (IBD), celiac disease and food protein-induced gastrointestinal allergy 
(FPGIA), vitamin D and zinc levels are particularly reduced [52-54]. Although poor absorption 
is a hallmark of these intestinal diseases, a modulatory effect of these nutrients, whereby 
imbalance of one nutrient can affect circulating concentrations of the other, cannot be 
excluded. Associations between childhood wheezing and asthma, when maternal intake of 
vitamin D and zinc, as well as vitamin E, is inadequate, have also been described [55] and 
zinc and vitamin D monitoring and supplementation have been suggested as a potential way 
to control wheezing in children [56]. 
Mutations in SLC30A10, which prevent ZnT10 expression and function, lead to a toxic 
accumulation of Mn in the brain, known as manganism. This is a Parkinson-like disease, 
except patients are not responsive to treatment with L-DOPA or dopamine agonists [57], but 
instead, to chelation therapy [58]. Hypovitaminosis D is prevalent in patients with early 
Parkinson’s disease (PD) [59, 60] and serum 25OHD levels have been shown to correlate 
with the severity of PD [61]. It would be revealing to examine whether in these patients, 
hypovitaminosis D would also affect ZnT10 expression or function, and if Mn levels are 
altered as a consequence.  
Our current data corroborates previous reports and brings to light new findings on the 
molecular role of vitamin D3 on the homeostasis of iron, manganese and several 
nutrient/drug transporters, as well as phase I and II enzymes. In particular for zinc and 
manganese homeostasis, our finding that vitamin D3 regulates SLC30A10 could trigger future 
work that assesses a possible role of Zn or Mn supplementation or chelation, alongside 
vitamin D3 administration, in the treatment of specific illnesses, such as osteoporosis and PD. 
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